In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

BMS and Solvay Pharmaceuticals develop obesity compound

Executive Summary

Bristol-Myers Squibb and Solvay Pharmaceuticals BV (cardiology, gastroenterology, mental health, and hormone replacement therapies) will jointly develop and globally commercialize Solvay's compound SLV319 for obesity and other metabolic disorders.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • Co-Promotion
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register